iPath ETNs and Their Risks

The iPath brand, owned and issued by Barclays Bank, has been one of the most prominent ETN issuers in the commodity and volatility space. iPath ETNs cover crude oil, natural gas, precious metals, broad commodity indices, and volatility products. Understanding iPath products provides concrete examples of how ETN structure creates distinct risks and how those risks have materialized in real investor losses.

iPath Product Portfolio and History

Barclays introduced the iPath brand in the early 2000s, recognizing investor appetite for commodity exposure that didn't require physical ownership or futures account management. iPath quickly became synonymous with commodity ETNs, growing to billions in assets under management across dozens of products. The brand's prominence made iPath ETNs default choices for many retail investors seeking commodity exposure through their brokerage accounts.

iPath offered simple commodity trackers—ETNs following crude oil, natural gas, copper, and other physical commodities. It also offered more complex products tracking commodity indices, volatility indices, and leveraged/inverse strategies. For example, iPath Series B Crude Oil ETN (OIL) provided exposure to front-month crude oil futures. iPath Series B Natural Gas ETN (GAZ) tracked natural gas. iPath S&P 500 VIX Short-Term Futures ETN (VXX) and its inverse (XIV) became among the most traded volatility products ever created.

The brand's success reflected genuine advantages. iPath ETNs provided cheaper access to commodity exposure than ETFs, with lower expense ratios, better tax efficiency, and in many cases, superior tracking of commodity indices. For investors who understood and accepted counterparty risk, iPath products worked effectively for years.

The Characteristics of Major iPath Products

The iPath crude oil and natural gas ETNs operated simply: they held futures contracts in those commodities and rolled them forward according to a published schedule. An investor buying iPath Crude Oil ETN received exposure to the near-month crude oil futures contract, with the fund handling the rolling mechanics automatically. This was more convenient and cheaper than an investor buying futures directly.

The natural gas ETN operated identically—it tracked front-month natural gas futures with automatic rolling. The fund charged roughly 0.50% annually, well below what a physical storage ETF would charge for actual natural gas.

More complex iPath products tracked commodity indices like the Bloomberg Commodity Index or the S&P Commodity Futures Index. These products provided diversified commodity exposure without requiring investors to build their own rolling schedules across multiple commodity contracts. The simplicity was appealing to investors who wanted commodity allocation but lacked the sophistication to construct diversified futures portfolios themselves.

iPath Volatility Products and Tail Risk

The most problematic iPath products were the volatility ETNs, particularly VXX (short-term VIX exposure) and XIV (inverse short-term VIX). These products became wildly popular with retail investors seeking to trade volatility or express short-volatility views without options trading. At their peak, these products had billions in assets and enormous trading volumes.

VXX was designed to provide exposure to short-term VIX futures. The VIX is the implied volatility of S&P 500 index options—a measure of expected stock market turbulence. Ironically, the VIX tends to spike precisely when stock markets are panicking, making short-volatility products profitable in calm markets but potentially catastrophic during crises.

XIV, the inverse product, made money when volatility was falling and lost money during volatility spikes. The product attracted investors seeking to bet against volatility or hedge long equity portfolios with short-volatility positions. The mechanics made sense in theory: during the years of falling volatility (2013-2017), XIV was one of the best performing funds on the market, returning 160%+ annualized in some years.

This exceptional performance created a moral hazard problem. Investors piled into XIV and similar products, using leverage and concentrating their positions. The issuer (Barclays) faced mounting counterparty risk from the billions in XIV notional exposure they had written. Meanwhile, the structure of the product—rolling short-term VIX futures—created inherent mechanical instability during volatility spikes.

The February 2018 XIV Implosion

On February 5, 2018, the S&P 500 fell 3.6% in a single trading session—the largest single-day decline in percentage terms since the election in November 2016. Volatility spiked from 17 to 36 in hours. The VIX jumped so sharply that short-volatility products faced immediate catastrophic losses.

For the short-term VIX futures that XIV held, losses were enormous. A 3.6% decline in stocks typically translates to a 20-30% or greater rise in short-term volatility. The XIV position, which had been profitable throughout 2017, faced a loss of 75% of its value in a single trading day.

Barclays, as the issuer, faced a decision: honor the note and allow XIV holders to receive their losses, or consider alternatives. With XIV facing the prospect of wiping out, trading became chaotic. The prospectus contained a provision allowing Barclays to liquidate the fund if funding costs became prohibitively expensive or if the issuer's credit risk rose too high. On the morning of February 5, with the market still falling and volatility rising, Barclays announced that XIV would be liquidated.

This liquidation meant that holders of XIV securities would receive a cash payment reflecting the fund's value on the liquidation date. But because volatility continued to spike throughout February 5 and into subsequent days, the liquidation price was far below where XIV had traded before the announcement. Investors who owned XIV at the close of February 2 faced a 95% loss when they received the final liquidation payout.

Moreover, many investors were unable to exit positions at any reasonable price. Trading halted in anticipation of the liquidation announcement. Some investors who held XIV in retirement accounts or non-trading accounts found themselves locked in before they could react. The speed of collapse—from a profitable, liquid investment to worthless paper in hours—illustrated the hidden risks of ETN structure.

The Mechanics of the XIV Catastrophe

The collapse revealed several ETN risks simultaneously. First, the product had been marketed to retail investors as a tactical trading tool, but the leverage embedded in the structure made catastrophic losses possible in single trading sessions. While the issuer had posted collateral, the collateral didn't cover the potential loss from a volatility spike of the magnitude that occurred.

Second, the liquidation clause in the prospectus, which gave Barclays the right to shut down the fund during market stress, proved to be a hidden embedded risk. Investors believed they could exit positions freely. But during the precise moment when exit was most important—during a sharp move against their position—the issuer exercised its right to liquidate unilaterally.

Third, the counterparty risk became manifest in an unexpected way. The risk wasn't that Barclays would go bankrupt—Barclays remained financially stable throughout. The risk was that Barclays's financial incentives diverged from investor interests. With XIV facing massive losses, Barclays preferred to liquidate and end the exposure rather than continue honoring its obligation while the fund remained unprofitable.

The Aftermath and Regulatory Response

The February 2018 XIV collapse triggered regulatory responses. The SEC examined ETN structures and issued updated guidance on ETN risk disclosures. FINRA issued notices reminding brokers to ensure retail investors understood ETN risks. The event also spurred investor lawsuits against Barclays, alleging inadequate disclosure of the liquidation risk and that the liquidation was executed in bad faith.

For other iPath products holding commodity futures, the event damaged investor confidence. Some institutions, including the SEC and major financial advisors, began recommending that retail investors avoid ETNs entirely in favor of ETFs with equivalent exposure. Assets in iPath commodity ETNs began a gradual decline as investors reallocated to ETF alternatives.

However, Barclays continued to offer iPath commodity products after 2018. The crude oil and natural gas ETNs, which didn't have the embedded leverage and liquidation risks of volatility products, continued operating. Some investors maintained that commodity iPath ETNs remained reasonable choices for accessing commodities at lower cost than equivalent ETFs, provided investors understood and accepted counterparty risk.

Lessons for ETN Investors

The iPath experience offers several lessons. First, prospectus provisions regarding liquidation rights must be read carefully and understood. An ETN might promise to track an index, but if the prospectus contains a provision allowing the issuer to liquidate during market stress, that risk is real and can be activated.

Second, products that have performed exceptionally well over trailing periods often contain hidden leverage or tail risks. A volatility ETN that returned 160% per year was embedding extreme leverage and was essentially unhedged against the very tail risk that made it profitable. When tail risk materialized, losses were symmetrically catastrophic.

Third, leverage and financial products aimed at tactical trading create risks that don't materialize until they do, suddenly. Thousands of retail investors who bought XIV to "make a quick trade" or "hedge volatility" found their entire positions liquidated during the very market stress when they most wanted to hold them.

Assessing Current iPath Products

As of 2025, iPath remains an active issuer under Barclays. The crude oil, natural gas, and broad commodity indices continue operating. These products still carry counterparty risk, but the experience since 2018 has been uneventful. Barclays remains financially stable, and these commodity products don't have the embedded leverage or exotic tail risk of volatility products.

For investors considering iPath commodity ETNs, the question is straightforward: are you comfortable accepting Barclays Bank's counterparty risk in exchange for lower expense ratios and better tracking than ETF alternatives? Barclays's credit rating, capital ratios, and stress test performance should be monitored. The 2008 financial crisis and 2018 XIV collapse are both more than five and fifteen years in the past respectively, but they remain instructive about what can happen when financial institutions face simultaneous mark-to-market losses and investor runs.

The iPath story illustrates that counterparty risk in ETNs is not theoretical. Real investors lost real money because an ETN issuer liquidated their positions during the precise moment those positions were most painful to exit. Understanding this history is essential context for any ETN investment decision.

References

• SEC Division of Investment Management. "Exchange-Traded Notes: Risks and Disclosures." Risk Alerts, 2013-2018.
• FINRA Regulatory Notice 12-47. "Enhanced Oversight of Exchange-Traded Notes."
• Barclays Bank. iPath Series B Prospectuses and Annual Reports. 2014-2025.
• Federal Reserve Board. "Barclays PLC Supervisory Capital Assessment Program Results." 2013-2024.